Patents by Inventor Yuji Kasuya
Yuji Kasuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082413Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 3, 2023Publication date: March 14, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Publication number: 20240026030Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: September 12, 2023Publication date: January 25, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Publication number: 20240000954Abstract: A complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention. Furthermore, a complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention.Type: ApplicationFiled: November 11, 2021Publication date: January 4, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken ISHII, Takato KUSAKABE, Yuji KASUYA, Nao JONAI, Fumihiko TAKESHITA, Isshin TANAKA, Emi KUROSAWA, Kyosuke SUZUKI, Tetsufumi KOGA, Yoshihiro MIYAJI
-
Patent number: 11795236Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting positionType: GrantFiled: September 13, 2018Date of Patent: October 24, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11633493Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: March 24, 2020Date of Patent: April 25, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: 11584800Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11261261Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: March 1, 2022Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11185594Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: April 6, 2015Date of Patent: November 30, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yusuke Ogitani, Yuki Abe
-
Patent number: 11015202Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: GrantFiled: December 20, 2018Date of Patent: May 25, 2021Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi
-
Patent number: 10973924Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: September 26, 2018Date of Patent: April 13, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Publication number: 20200385486Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: August 19, 2020Publication date: December 10, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Patent number: 10808006Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: GrantFiled: February 15, 2019Date of Patent: October 20, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Publication number: 20200282073Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 24, 2020Publication date: September 10, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Patent number: 10729782Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.Type: GrantFiled: November 22, 2017Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
-
Patent number: 10731159Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: November 22, 2019Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20200080086Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: November 22, 2019Publication date: March 12, 2020Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Patent number: 10533176Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: October 30, 2017Date of Patent: January 14, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20190233466Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: ApplicationFiled: February 15, 2019Publication date: August 1, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Publication number: 20190112606Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: ApplicationFiled: December 20, 2018Publication date: April 18, 2019Applicants: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken ISHII, Kouji KOBIYAMA, Taiki AOSHI, Fumihiko TAKESHITA, Yuji KASUYA, Takako NIWA, Makoto KOIZUMI
-
Publication number: 20190077880Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: September 13, 2018Publication date: March 14, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE